Outpatient treatment of alcohol use disorder

ABSTRACT: Alcohol use disorder is highly prevalent and has a significant impact on individuals and society. Research suggests that physicians underutilize medications for relapse prevention even though there is good evidence to support pharmacotherapy for this. Moreover, in outpatient settings, benzodiazepines for alcohol withdrawal are sometimes prescribed in ways that may not be safe. The Quick Guide to Outpatient Treatment of Alcohol Use Disorder was created as part of a UBC Family Practice Resident Scholar Project. The guide was developed with feedback from physicians who have experience in addiction medicine, and was subsequently reviewed and approved by the British Columbia Centre on Substance Use to ensure it is consistent with the centre’s newly released clinical guidelines. The guide focuses on safe management of alcohol withdrawal in an outpatient setting and on relapse prevention. Physicians can use this supplementary resource along with practice guidelines and clinical judgment.


An easy-to-use guide produced as part of a UBC Family Practice Resident Scholar Project supports physicians prescribing medications to treat alcohol withdrawal symptoms and prevent relapse.


Alcohol is the most frequently used intoxicating substance in the world, and is responsible for substantial morbidity and mortality.[1] Numerous resources have been committed to managing health issues related to marijuana and opioid use, but in Canada, alcohol use continues to have a much greater societal and economic impact than all illegal drugs combined.[2] Alcohol is legal, highly available, and more socially accepted than other intoxicating substances.

Alcohol use disorder

Alcohol use disorder (AUD) is defined as a problematic pattern of alcohol use leading to clinically significant impairment or distress. It is a common primary care issue affecting approximately 2% to 9% of family practice patients.[3] The 12-month prevalence of AUD in North America is 8.5%.[1] In Canada, at least half of all alcohol consumed is in excess of Canada’s Low-Risk Alcohol Drinking Guidelines.[4]

The costs of AUD to individuals and society are immense and include accidents, violence, and suicide, as well as negative impacts on driving, school, work, interpersonal relationships, and physical health.[1]

Treatment of alcohol use disorder

Several studies have shown that treatments for AUD and alcohol withdrawal are underutilized.[5-14] Less than 33% of patients with AUD receive any treatment, and less than 5% receive medications as a part of treatment.[15] Some of the common barriers for physicians include a lack of knowledge about AUD and alcohol withdrawal, a lack of formal training in treating AUD, and a lack of familiarity with different treatment options and the benefits and risks of each option.[5,7-11,13,16,17] There are no clear data on which of these barriers is the most significant in terms of preventing more physicians from treating AUD and alcohol withdrawal in an outpatient setting.

Treatment of AUD includes widely known and well-accepted behavioral intervention programs. However, there is increasing evidence that medications can be used as well for both alcohol withdrawal syndrome and relapse prevention.[6,8,12,14,17-29] The number needed to treat (NNT) to either reduce heavy drinking or increase abstinence from alcohol for the two most commonly used medications (naltrexone and acamprosate) is 10 to 12,[30] which is substantially better than the NNT for medications used for many other medical disorders. However, evidence suggests that these medications are underutilized by prescribers.[5-13,18,19,31]

Traditionally, alcohol withdrawal has been treated with benzodiazepines (BZDs), but there is increasing awareness of problems associated with their use.[8,9,28,29] This has motivated researchers to find safer but still effective alternatives to use in outpatient settings. Evidence for gabapentin in treating mild to moderate alcohol withdrawal symptoms is increasing.[8,14,19-21,23,25,26,32] Head-to-head trials that have compared gabapentin and BZDs have shown gabapentin is as effective as lorazepam or chlordiazepoxide in treating mild to moderate alcohol withdrawal symptoms.[28,29] Naltrexone, an opioid antagonist, is considered first-line therapy for relapse prevention; it works by reducing the pleasurable and reinforcing effect of alcohol. Acamprosate, a GABA agonist/glutamate antagonist, is also commonly used for relapse prevention; it works by rebalancing neuronal brain changes that occur from chronic alcohol use.[33]

Prior to the 2019 release of the British Columbia Centre on Substance Use (BCCSU) Provincial Guideline for the Clinical Management of High-Risk Drinking and Alcohol Use Disorder,[34] there was little readily available information on outpatient management of alcohol withdrawal. The previous BC Guidelines outlined an approach for identifying and managing alcohol withdrawal in an outpatient setting, but this approach focused on using benzodiazepines in a home setting.[33] The pharmacological treatment listed in the previous BC Guidelines involves using diazepam for acute withdrawal symptoms and then naltrexone, acamprosate, or disulfiram for long-term relapse prevention. UpToDate has information on treating mild alcohol withdrawal with either BZD or gabapentin in an outpatient setting, and provides options for relapse prevention.[35] Other position papers provide information only on BZD use; they have not been updated to include gabapentin or other treatments.[3]

Guide to treating AUD

To address knowledge gaps regarding the treatment of AUD, we created a clinical resource for family physicians to use when considering treatment for a patient with suspected AUD. The Quick Guide to Outpatient Treatment of Alcohol Use Disorder [Figures 1A and 1B] was developed as part of a UBC Family Practice Resident Scholar Project. The guide focuses on the assessment, treatment, and monitoring of AUD, and relies on the Prediction of Alcohol Withdrawal Severity Scale (PAWSS) scoring system [Figure 2] for assessing the risk of alcohol withdrawal syndrome.[36] A 2018 study by St. Paul’s Hospital in Vancouver examined the usefulness of various predictive alcohol withdrawal severity scales and found the PAWSS score to be the most useful.[37]

The guide emphasizes the importance of behavioral interventions and provides details on medications that can be used to manage alcohol withdrawal safely in an outpatient setting and how to prevent relapse. Information on using BZDs in withdrawal management and cautions that should be exercised are also provided. Instructions for accessing PharmaCare coverage are included.

The guide is based on previous guidelines,[33] research, and expert opinion from local addiction medicine physicians, and was reviewed and approved by the BCCSU to ensure it is consistent with the 2019 provincial guideline.[34] Development of the guide was inspired by a similar quick reference guide to buprenorphine/naloxone.[38]

The guide was designed for easy use and distribution so that a wide range of primary care providers can become familiar with prescribing certain medications to treat AUD. This will make AUD treatment more accessible and affordable for patients and will improve treatment outcomes. AUD treatment should not have to be limited to specialized care. However, the guide was not designed to be a comprehensive resource, and its users are encouraged to seek support for challenging cases. There may be other treatment options that were excluded from the guide for the sake of simplicity.

While we were unable to critically assess the impact of the guide on prescribing practices during the Resident Scholar Project, we hope that we or another resident group will be able to do so in the future.

Summary

Alcohol is the most frequently used intoxicating substance in the world, and alcohol use disorder is a common primary care issue. Our guide was created to support family physicians in safely treating AUD and managing mild to moderate alcohol withdrawal. The guide focuses on pharmacotherapy and emphasizes the importance of using concurrent behavioral interventions. It can be used as a supplementary resource in an office setting, along with current practice guidelines and clinical judgment.

Acknowledgments

We would like to thank Dr Roger Walmsley, our residency project preceptor and ER physician with a focus on addiction medicine, as well as Dr Hector Baillie and Dr Heather Yule, academic site leads, for their input and guidance throughout the residency project. We would also like to thank Dr Theodore Jankowski, Dr Ramm Hering, and Dr Christy Sutherland, addiction medicine physicians who kindly provided input on the handout, as well as Ms Emily Wagner and Ms Amanda Giesler from the BC Centre on Substance Use for their generous help in reviewing and editing the handout.

Competing interests

None declared.


This article has been peer reviewed.


References

1.    American Psychiatric Association. Diagnostic and statis­tical manual of mental disorders. 5th ed. Washington, DC: APA;2013. doi:10.1176/­appi.books­.9780890425596­.744053.

2.    Rehm J, Baliunas D, Brochu S, et al. The costs of substance abuse in Canada 2002. Ottawa, ON: Canadian Centre on Substance Use and Addiction, 2006. Accessed 14 January 2018. www.ccsa.ca/sites/default/files/2019-05/ccsa-011332-2006.pdf.

3.    Muncie HL, Yasinian Y, Oge L. Outpatient management of alcohol withdrawal syndrome. Am Fam Physician 2013;88:589-595.

4.    Stockwell T, Zhao J, Thomas G. Should alcohol policies aim to reduce total alcohol consumption? New analyses of Canadian drinking patterns. Addict Res Theory 2009;17:135-151.

5.    Ducharme LJ, Knudsen HK, Roman PM. Trends in the adoption of medications for alcohol dependence. J Clin Psychopharmacol 2006;26:S13-S19.

6.    Donoghue K, Elzerbi C, Saunders R, et al. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: A meta-analysis. Addiction 2015;110:920-930.

7.    Finlay AK, Ellerbe LS, Wong JJ, et al. Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs. J Subst Abuse Treat 2017;77:38-43.

8.    Goh ET, Morgan MY. Review article: Pharmacotherapy for alcohol dependence – the why, the what and the wherefore. Aliment Pharmcol Ther 2017;45:865-882.

9.    Harris AHS, Ellerbe L, Reeder RN, et al. Pharmacotherapy for alcohol dependence: Perceived treatment barriers and action strategies among Veterans Health Administration service providers. Psychol Serv 2013;10:410-419.

10.    Mark TL, Kranzler HR, Poole VH, et al. Barriers to the use of medications to treat alcoholism. Am J Addict 2003;12:281-294.

11.    Martinez CP, Vakkalanka P, Ait-Daoud N. Pharmacotherapy for alcohol use disorders: Physicians’ perceptions and practices. Front Psychiatry 2016;7:182.

12.    Mirijello A, D’Angelo C, Ferrulli A, et al. Identification and management of alcohol withdrawal syndrome. Drugs 2015;75:353-365.

13.    Roman PM, Abraham AJ, Knudsen HK. Using medication-assisted treatment for substance use disorders: Evidence of barriers and facilitators of implementation. Addict Behav 2011;36:584-589.

14.    Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: A review. JAMA 2018;320:815-824.

15.    Spithoff S, Turner S, Gomes T, et al. First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario. Can Fam Physician 2017;63:e277-e283.

16.    Thomas CP, Wallack SS, Lee S, et al. Research to practice: adoption of naltrexone in alcoholism treatment. J Subst Abuse Treat 2003;24:1-11.

17.    Matusow H, Dickman SL, Rich JD, et al. Medication assisted treatment in US drug courts: Results from a nationwide survey of availability, barriers and attitudes. J Subst Abuse Treat 2013;44:473-480.

18.    Holbrook AM, Crowther R, Lotter A, et al. Diagnosis and management of acute alcohol withdrawal. CMAJ 1999;160:675-680.

19.    Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A systematic review and meta-analysis. JAMA 2014;311:1889-1900.

20.    Anton RF, Myrick H, Wright TM, et al. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry 2011;168:709-717.

21.    Bonnet U, Banger M, Leweke M, et al. Treatment of acute alcohol withdrawal with gabapentin: Results from a controlled two-center trial. J Clin Psychopharmacol 2003;23:514-519.

22.    Elholm B, Larsen K, Hornnes N, et al. Alcohol withdrawal syndrome: Symptom-triggered versus fixed-schedule treatment in an outpatient setting. Alcohol Alcohol 2011;46:318-323.

23.    Hammond CJ, Niciu MJ, Drew S, Arias AJ. Anticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disorders. CNS Drugs 2015;29:293-311.

24.    Krystal JH, Cramer JA, Krol WF, et al. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001;354:1734-1739.

25.    Leung JG, Hall-Flavin D, Nelson S, et al. The role of gabapentin in the management of alcohol withdrawal and dependence. Ann Pharmacother 2015;49:897-906.

26.    Leung JG, Rakocevic DB, Allen ND, et al. Use of a gabapentin protocol for the management of alcohol withdrawal: a preliminary experience expanding from the consultation-liaison psychiatry service. Psychosomatics 2018;59:496-505.

27.    Molero Y, Zetterqvist J, Binswanger IA, et al. Medications for alcohol and opioid use disorders and risk of suicidal behavior, accidental overdoses, and crime. Am J Psychiatry 2018;175:970-978.

28.    Myrick H, Malcolm R, Randall PK, et al. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res 2009;33:1582-1588.

29.    Stock CJ, Carpenter L, Ying J, Greene T. Gabapentin versus chlordiazepoxide for outpatient alcohol detoxification treatment. Ann Pharmacother 2013;47:961-969.

30.    Rösner S, Hackl-Herrwerth A, Leucht S, et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010;12:CD001867.

31.    Kirkey S. Pills can help people control risky drinking, so why aren’t doctors prescribing them? The National Post, 2019. Accessed 5 March 2019. https://nationalpost.com/news/pills-can-help-people-control-risky-drinking-so-why-arent-doctors-prescribing-them.

32.    Mason BJ, Quello S, Shadan F. Gabapentin for the treatment of alcohol use disorder. Expert Opin Investig Drugs 2018;27:113-124.

33.    Government of British Columbia. BC guidelines. Problem drinking, 2013. Accessed 10 December 2018. www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/bc-guidelines/problem-drinking.

34.    British Columbia Centre on Substance Use. Provincial guideline for the clinical management of high-risk drinking and alcohol use disorder. 2019. Accessed 19 August 2020. www.bccsu.ca/wp-content/uploads/2020/03/AUD-Guideline.pdf.

35.    Holt SR, Tetrault JM. Ambulatory management of alcohol withdrawal. UpToDate. Accessed 2 February 2019. www.uptodate.com/contents/ambulatory-management-of-alcohol-withdrawal.

36.    Maldonado JR, Sher Y, Asshouri JF, et al. The “Prediction of Alcohol Withdrawal Severity Scale” (PAWSS): Systematic literature review and pilot study of a new scale for the prediction of complicated alcohol withdrawal syndrome. Alcohol 2014;48:375-390.

37.    Wood E, Albarqouni L, Tkachuk S, et al. Will this hospitalized patient develop severe alcohol withdrawal syndrome? The rational clinical examination systematic review. JAMA 2018;320:825-833.

38.    Caddy P, Smith K. A quick-reference guide for prescribing buprenorphine/naloxone (Suboxone) in the outpatient setting. BCMJ 2018;60:392-397.


Dr Molavi completed a family medicine residency at UBC’s Nanaimo site and enhanced skills training in addiction medicine through UBC, and is now a family physician and a staff addiction medicine physician at Nanaimo Regional General Hospital. Dr Guruge also completed a family medicine residency at UBC’s Nanaimo site and is currently practising as a family physician in White Rock. Dr Kelly completed family medicine residency at UBC’s Strathcona site and is currently practising as a family physician in Comox.

Armon Molavi, MD, Sulara Guruge, MD, Peter Kelly, MD. Outpatient treatment of alcohol use disorder. BCMJ, Vol. 62, No. 8, October, 2020, Page(s) - Clinical Articles.



Above is the information needed to cite this article in your paper or presentation. The International Committee of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.

About the ICMJE and citation styles

The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.

An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.

BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:

  • Only the first three authors are listed, followed by "et al."
  • There is no period after the journal name.
  • Page numbers are not abbreviated.


For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit www.icmje.org

BCMJ Guidelines for Authors

Leave a Reply